|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
U.S. Soccer Legend Kasey Keller Reveals Lymphoma Journey
2
Why Is Lung Health Key to Survivorship After Cancer Treatment?
3
New Combination Treatment Approach Studied in Pancreatic Cancer
4
The Power of Personalized Care in Breast Cancer Treatment
5